← Back to patent-cliff list
Nilotinib Tartrate
Tier C — Watch / tradeNilotinib Tartrate
Azurity Pharmaceuticals Inc
Originator
2024
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Bcr-Abl
Brand：Danziten
Indications (approved)：髓系白血病加速期, Chronic-phase myeloid leukaemia
Regional status
US
Approved
2024-11-07
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Nilotinib Tartrate?
Approved indications include: 髓系白血病加速期, Chronic-phase myeloid leukaemia.
When does the Nilotinib Tartrate patent expire?
No public expiry year is available for Nilotinib Tartrate yet; this page updates once verified.
How do I get a quote for Nilotinib Tartrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01